Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men

Completed · Phase 2

Conditions studied: Amphetamine-Related Disorders, HIV, HIV Infections

In brief

This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors among methamphetamine-using men who have sex with men (MSM) by combining a biomedical intervention with a behavioral intervention. The behavioral intervention will consist of an 8-week course of contingency management (CM) through which participants will be reinforced for testing negative for methamphetamine metabolites during periodic urine analyses. The biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be administered after an unanticipated HIV risk exposure (i.e., engaging in either receptive or insertive anal sex without a condom with someone who is HIV-positive or of unknown status). In combining these two interventions, this study seeks to evaluate the combined intervention's effects on sexual risk behaviors and methamphetamine use.

Key facts

Study ID

NCT00856323

Run by

Friends Research Institute, Inc.

People needed

53

Starts

2009-01-01

Expected to finish

2010-12-01

Last updated by the study team

2016-09-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Individual must identify as a male who has sex with other men (MSM);
• At least 18 years of age;
• HIV negative serostatus on baseline rapid oral HIV antibody test;
• Self-reported methamphetamine use within the previous 72 hours and test positive for methamphetamine metabolites at baseline;
• Self-reported unprotected anal intercourse (either receptive or insertive) with an HIV-positive or status unknown partner within the previous 3 months;
• Self-reports no previous hypersensitivity to any of the components of Truvada (tenofovir disoproxil fumarate or emtricitabine);
• Willing to comply with study requirements (i.e., monitored urine testing three times per week, meet with physician within first week of enrollment, begin medication immediately following an unexpected high-risk sexual exposure, and contact the clinic and meet with physician within 92 hours of unexpected high-risk sexual exposure).

You may not qualify if…

• Does not identify as a male who has sex with other men;
• Under 18 years of age;
• HIV positive, by self-report or as indicated by the results on the baseline rapid oral HIV antibody test;
• Self-reports any previous hypersensitivity to any of the components of Truvada;
• Has not used methamphetamine in the previous 72 hours and does not test positive for methamphetamine metabolites;
• Has not had unprotected anal intercourse with an HIV-positive or status unknown partner within the previous 3 months;
• Unwilling to comply with study requirements.

Where it is running

• Friends Community Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.